CA3134587A1 - Mirikizumab for use in a method of treating crohn's disease - Google Patents

Mirikizumab for use in a method of treating crohn's disease Download PDF

Info

Publication number
CA3134587A1
CA3134587A1 CA3134587A CA3134587A CA3134587A1 CA 3134587 A1 CA3134587 A1 CA 3134587A1 CA 3134587 A CA3134587 A CA 3134587A CA 3134587 A CA3134587 A CA 3134587A CA 3134587 A1 CA3134587 A1 CA 3134587A1
Authority
CA
Canada
Prior art keywords
mirikizumab
administered
weeks
dose
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3134587A
Other languages
English (en)
French (fr)
Inventor
Stuart William FRIEDRICH
Paul Frederick POLLACK
Jay Lawrence TUTTLE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3134587A1 publication Critical patent/CA3134587A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
CA3134587A 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease Pending CA3134587A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
US62/836,910 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Publications (1)

Publication Number Publication Date
CA3134587A1 true CA3134587A1 (en) 2020-10-29

Family

ID=70554215

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3134587A Pending CA3134587A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Country Status (17)

Country Link
US (1) US20220040299A1 (enExample)
EP (1) EP3958897A1 (enExample)
JP (3) JP7297930B2 (enExample)
KR (2) KR20250153865A (enExample)
CN (2) CN119700968A (enExample)
AU (2) AU2020263238C1 (enExample)
BR (1) BR112021018930A2 (enExample)
CA (1) CA3134587A1 (enExample)
EA (1) EA202192532A1 (enExample)
IL (2) IL286818B1 (enExample)
MA (1) MA55756A (enExample)
MX (1) MX2021012848A (enExample)
SG (1) SG11202110619XA (enExample)
TW (2) TWI850365B (enExample)
UA (1) UA128657C2 (enExample)
WO (1) WO2020219314A1 (enExample)
ZA (1) ZA202108094B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20140049B1 (ar) 2013-03-08 2021-08-17 Lilly Co Eli أجسام مضادة ترتبط بـ il-23
EP3693007A1 (en) 2013-03-15 2020-08-12 Amgen, Inc Methods for treating crohn's disease using an anti-il23 antibody
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
AU2017312049A1 (en) * 2016-08-19 2019-02-21 Janssen Biotech, Inc. Methods of treating Crohn's Disease with an anti-NKG2D antibody
KR20200037258A (ko) * 2017-07-10 2020-04-08 람밤 메드-테크 엘티디. 생물학적 약물로 치료받은 피험자에서 중화 항체 수준 평가용 분석법 및 맞춤 의료에서 이의 사용
TWI850365B (zh) * 2019-04-22 2024-08-01 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Also Published As

Publication number Publication date
CN119700968A (zh) 2025-03-28
JP2022530397A (ja) 2022-06-29
JP7761614B2 (ja) 2025-10-28
AU2020263238C1 (en) 2024-02-22
KR20210142704A (ko) 2021-11-25
AU2023265759A1 (en) 2023-12-07
TW202103734A (zh) 2021-02-01
US20220040299A1 (en) 2022-02-10
BR112021018930A2 (pt) 2022-01-18
UA128657C2 (uk) 2024-09-18
IL324048A (en) 2025-12-01
CN113677366A (zh) 2021-11-19
EP3958897A1 (en) 2022-03-02
WO2020219314A1 (en) 2020-10-29
JP7297930B2 (ja) 2023-06-26
EA202192532A1 (ru) 2022-01-21
AU2020263238A1 (en) 2021-11-04
ZA202108094B (en) 2025-05-28
NZ781127A (en) 2025-06-27
IL286818A (en) 2021-10-31
AU2020263238B2 (en) 2023-08-17
SG11202110619XA (en) 2021-11-29
TWI850365B (zh) 2024-08-01
JP2023116680A (ja) 2023-08-22
IL286818B1 (en) 2025-11-01
JP2025148449A (ja) 2025-10-07
MX2021012848A (es) 2021-12-10
KR102869852B1 (ko) 2025-10-14
KR20250153865A (ko) 2025-10-27
TW202515610A (zh) 2025-04-16
MA55756A (fr) 2022-03-02

Similar Documents

Publication Publication Date Title
US20250034243A1 (en) Methods of treating ulcerative colitis
Macaluso et al. The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases
AU2023265759A1 (en) Mirikizumab for use in a method of treating Crohn's Disease
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона
HK40101440A (en) Mirikizumab in the treatment of ulcerative colitis
EA049081B1 (ru) Способы лечения язвенного колита
HK40036550A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550B (en) Mirikizumab in the treatment of ulcerative colitis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211021

EEER Examination request

Effective date: 20211021

EEER Examination request

Effective date: 20211021

EEER Examination request

Effective date: 20211021

EEER Examination request

Effective date: 20211021

EEER Examination request

Effective date: 20211021